The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...

Charles River expanded the Memphis facility in November 2022, adding nine processing suites to its 16 clean rooms at the site ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

Patients with childhood and young adult cancer have an increased long-term risk for diabetes, noted as early as 10 years ...